Recent Advances in Gene Therapy for Hemophilia: Projecting the Perspectives

Area of Science:

• Genetics and Molecular Biology
• Hematology
• Gene Therapy

Background:

• Hemophilia A and B are X-linked genetic disorders caused by mutations in F8 (factor VIII) or F9 (factor IX) genes, respectively.
• Severe hemophilia results in <1% factor activity, leading to spontaneous or traumatic bleeding, complications, and mortality.
• Current treatments involve lifelong, expensive replacement therapies with clotting factors or monoclonal antibodies.

Purpose of the Study:

• To review traditional and modern treatment approaches for hemophilia A and B.
• To focus on gene therapy as a potentially transformative treatment modality.
• To summarize recent technological advances and gene therapeutics in the pipeline.

Main Methods:

• Literature review of traditional hemophilia treatments.
• Critical review of gene therapy approaches for hemophilia A and B.
• Analysis of recent technological advancements and emerging gene therapeutics.

Main Results:

• Gene therapy offers a potential one-off in vivo vector delivery for long-term endogenous expression of factor VIII or IX.
• Gene therapy may overcome limitations of traditional treatments, including cost and immune responses to antibody drugs.
• Several gene therapeutics are in the pipeline, indicating rapid advancement in the field.

Conclusions:

• Gene therapy is identified as the most promising future treatment for hemophilia.
• It holds the potential to significantly improve patient outcomes by addressing the challenges of current therapies.
• Ongoing research and development in gene therapeutics are crucial for realizing this potential.